Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data by Cole, Michelle J. et al.
RESEARCH ARTICLE Open Access
Ten years of external quality assessment
(EQA) of Neisseria gonorrhoeae
antimicrobial susceptibility testing in
Europe elucidate high reliability of data
Michelle J. Cole1* , Nerteley Quaye2, Susanne Jacobsson3, Michaela Day1, Elizabeth Fagan4, Catherine Ison5,
Rachel Pitt1, Shila Seaton4, Neil Woodford1, Angelika Stary6, Sonja Pleininger7, Tania Crucitti8, Blaženka Hunjak9,
Panayiota Maikanti10, Steen Hoffmann11, Jelena Viktorova12, Susanne Buder13, Peter Kohl13, Eva Tzelepi14,
Eirini Siatravani14, Eszter Balla15, Guðrún Svanborg Hauksdóttir16, Lisa Rose17, Paola Stefanelli18, Anna Carannante18,
Gatis Pakarna19, Francesca Mifsud20, Rosann Zammit Cassar20, Ineke Linde21, Thea Bergheim22, Martin Steinbakk23,
Beata Mlynarczyk-Bonikowska24, Maria-José Borrego25, Jill Shepherd26, Peter Pavlik27, Samo Jeverica28,
Julio Vazquez29, Raquel Abad29, Sabrina Weiss1,30,31, Gianfranco Spiteri31† and Magnus Unemo3†
Abstract
Background: Confidence in any diagnostic and antimicrobial susceptibility testing data is provided by appropriate and
regular quality assurance (QA) procedures. In Europe, the European Gonococcal Antimicrobial Susceptibility Programme (Euro-
GASP) has been monitoring the antimicrobial susceptibility in Neisseria gonorrhoeae since 2004. Euro-GASP includes an external
quality assessment (EQA) scheme as an essential component for a quality-assured laboratory-based surveillance programme.
Participation in the EQA scheme enables any problems with the performed antimicrobial susceptibility testing to be identified
and addressed, feeds into the curricula of laboratory training organised by the Euro-GASP network, and assesses the capacity of
individual laboratories to detect emerging new, rare and increasing antimicrobial resistance phenotypes. Participant
performance in the Euro-GASP EQA scheme over a 10 year period (2007 to 2016, no EQA in 2013) was evaluated.
Methods: Antimicrobial susceptibility category and MIC results from the first 5 years (2007–2011) of the Euro-GASP EQA were
compared with the latter 5 years (2012–2016). These time periods were selected to assess the impact of the 2012 European
Union case definitions for the reporting of antimicrobial susceptibility.
Results: Antimicrobial susceptibility category agreement in each year was ≥91%. Discrepancies in susceptibility categories
were generally because the MICs for EQA panel isolates were on or very close to the susceptibility or resistance breakpoints.
A high proportion of isolates tested over the 10 years were within one (≥90%) or two (≥97%) MIC log2 dilutions of the
modal MIC, respectively. The most common method used was Etest on GC agar base. There was a shift to using
breakpoints published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in the latter 5 years,
however overall impact on the validity of results was limited, as the percentage categorical agreement and MIC
concordance changed very little between the two five-year periods.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: michelle.cole@phe.gov.uk
†Gianfranco Spiteri and Magnus Unemo are Joint senior authors
1Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI)
Reference Unit, National Infection Service, Public Health England, London, UK
Full list of author information is available at the end of the article
Cole et al. BMC Infectious Diseases          (2019) 19:281 
https://doi.org/10.1186/s12879-019-3900-z
(Continued from previous page)
Conclusions: The high level of comparability of results in this EQA scheme indicates that high quality data are produced by
the Euro-GASP participants and gives confidence in susceptibility and resistance data generated by laboratories performing
decentralised testing.
Keywords: Gonorrhoea, EUCAST, Euro-GASP, European Union (EU), European economic area (EEA)
Background
Gonorrhoea is the second most common bacterial sexu-
ally transmitted infection (STI) worldwide, with a global
estimate of 78 million new cases among adults in 2012
[1]. If untreated, gonorrhoea can result in complications
and sequelae such as pelvic inflammatory disease, ec-
topic pregnancy and infertility [2]. In the absence of an
effective vaccine, antimicrobial treatment along with ap-
propriate prevention, diagnostics and surveillance, is the
mainstay in the clinical and public health management
of gonorrhoea and prevention of these complications.
However, due to the emergence and spread of antimicro-
bial resistance in the causative agent, Neisseria gonor-
rhoeae, most previously used therapeutic agents can no
longer be recommended for first-line treatment [3]. Dual
antimicrobial therapy, mainly ceftriaxone 250–500 mg
plus azithromycin 1–2 g, is the current recommended
empirical first-line treatment for gonorrhoea in many
countries [4]. As strongly emphasized in the WHO glo-
bal action plan [5] and the European response plan [6]
to control multidrug-resistant N. gonorrhoeae, enhanced
worldwide, quality-assured surveillance of gonococcal
antimicrobial susceptibility is crucial in order to ensure
the effectiveness of the recommended empiric treatment,
to monitor antimicrobial resistance trends, and to iden-
tify new emerging resistance.
In general, confidence in any diagnostic and antimicrobial
susceptibility testing data is provided by appropriate and
regular quality assurance (QA) procedures. These include
validations of testing methods used, internal quality controls,
and quality assessments such as internal quality assessment
and, importantly, external quality assessment (EQA). In Eur-
ope, the European Gonococcal Antimicrobial Susceptibility
Programme (Euro-GASP) has been monitoring the anti-
microbial susceptibility in N. gonorrhoeae since 2004 [7–11].
Isolates are tested either centrally or via a decentralised test-
ing model where antimicrobial susceptibility testing is per-
formed in laboratories in participating countries after
fulfilling set quality criteria. Criteria include acceptable per-
formance in the EQA and good comparability between the
laboratories own national susceptibility testing data and sus-
ceptibility data generated by centralised susceptibility testing
[11]. Euro-GASP includes an EQA scheme as an essential
component for a quality-assured laboratory-based surveil-
lance programme [12]. This EQA scheme aims to ensure
high-quality, accurate and comparable susceptibility data
between and within testing laboratories. Furthermore, suc-
cessful performance in the EQA is one of the quality criteria
(introduced in 2010) required for Euro-GASP to include sus-
ceptibility data generated by laboratories performing decen-
tralised testing [11]. Participation in the EQA scheme
enables any problems with the performed antimicrobial sus-
ceptibility testing to be identified and addressed, feeds into
the curricula of laboratory training organised by the
Euro-GASP network, and assesses the capacity of individual
laboratories to detect emerging new, rare and increasing
antimicrobial resistance phenotypes.
The first Euro-GASP EQA gonococcal strain panel was
distributed to the newly created Euro-GASP network in
2003 [13], before the first sentinel susceptibility study in
2004 [9]. The results showed an overall susceptibility cat-
egory agreement of only 70% and a crucial need for en-
hanced standardisation of the susceptibility testing
methods used in Europe. In 2007, the Euro-GASP EQA
scheme was re-established and subsequently run until
2009 as part of the European Surveillance of Sexually
Transmitted Infections (ESSTI) programme [14]. Since
2010, the EQA has been co-ordinated by the European
Centre for Disease Prevention and Control (ECDC).
The aims of the present study were to evaluate the per-
formance of the Euro-GASP EQA over a 10-year period
(2007 to 2016) and to compare the results of the first 5
years (2007–2011) with the latter 5 years (2012–2016; no
EQA in 2013) in order to assess whether Euro-GASP data
provide a high-quality and valid picture of gonococcal anti-
microbial resistance in the European Union/European Eco-
nomic Area (EU/EEA), i.e. on which treatment
recommendations can be based. These time periods were
selected to additionally assess the impact of the 2012 Euro-
pean Union case definitions for the reporting of antimicro-
bial susceptibility (http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2012:262:0001:0057:EN:PDF).
Methods
EQA panel and antimicrobial susceptibility testing
methods
The EQA gonococcal strain panels were selected by
Public Health England (PHE) and Örebro University
Hospital, Sweden. From 2007 to 2009, the EQA was run
annually, consisted of 30 cultures of N. gonorrhoeae (10
strains in triplicate to measure intra-laboratory reprodu-
cibility), and was distributed by PHE to 19 participating
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laboratories in 2007 and 2008, and 16 laboratories in
2009. Since 2010, the United Kingdom National External
Quality Assessment Service (UK NEQAS) has distrib-
uted the EQA panels. The EQA panels from 2010 to
2016 (no EQA was performed in 2013) consisted of 65
gonococcal isolates, some in duplicate or triplicate. In
2010, 15 isolates were distributed in two EQAs; ten iso-
lates in March (19 laboratories) and five in October (20
laboratories). In 2011, two panels of five isolates each
were distributed in February (20 laboratories) and Octo-
ber (21 laboratories). Ten isolates were distributed in
one panel in 2012 (22 laboratories), 2014 (21 laborator-
ies), 2015 (26 laboratories), and 2016 (27 laboratories).
The gonococcal strains in the EQA panels demonstrated
a range of antimicrobial susceptibility profiles to thera-
peutic agents. The gonococci were selected from clinical
isolates and a panel of well characterised strains, includ-
ing current WHO reference strains [15]. Over the 10
years, 46 different strains were included in the EQAs;
ten of these strains were included in more than one dis-
tribution (four strains in three distributions, two strains
in two and four distributions (four strains in total), one
strain in five and another in seven distributions). Of the
ten different strains, eight (WHO F, G, K, L, M, N, O, P)
are incorporated in the WHO N. gonorrhoeae control
panel [15] and were included a total of 29 times.
The laboratories participating in the EQA scheme
were requested to test the isolates using their own rou-
tine antimicrobial susceptibility testing methodology and
standard operating procedures, against a panel of thera-
peutically relevant antimicrobial agents, ideally ceftriax-
one, cefixime (included since 2010), azithromycin,
ciprofloxacin, spectinomycin, and gentamicin (included
since 2010). Penicillinase production (β-lactamase test-
ing) was also monitored where performed. The anti-
microbial susceptibility testing methodologies, including
media used, and the guidelines/breakpoints used for
each antimicrobial agent were requested. Data on the
clinical breakpoints (interpretative criteria) used by each
laboratory for each individual agent was available until
2012. Post 2012, data were collected on adherence to
published breakpoints. For each isolate tested, minimum
inhibitory concentrations (MICs) (mg/L) or zones of in-
hibition (mm), as well as the susceptibility category (sus-
ceptible (S), intermediate susceptible (I), or resistant (R))
were reported. Results were reported directly to PHE
until 2012 and to UK NEQAS from 2014.
Analysis and interpretation of the results
For the analysis, Etest (or more rarely other MIC gradi-
ent strip tests such as the Oxoid M.I.C.Evaluator strips
or the Liofilchem MIC Test Strips) whole MIC log2 dilu-
tions were used. The minimum, maximum and modal
MIC of each strain was established. To avoid relying
upon one set of MIC results from the laboratory that se-
lected the isolates, the modal MIC was used as the ‘ex-
pected’ MIC. The number of MICs within one MIC log2
dilution of the modal MIC (essential agreement), as well
as number of MICs within two and > 2 MIC log2 dilu-
tions of the modal MIC for each strain was established
for all years and for each five-year period (2007–2011
and 2012–2016). The MICs for the eight WHO strains
(total of 29 appearances in the EQA) were analysed to
assess comparability, consistency and performance of
participating laboratories over the 10 years.
The consensus antimicrobial susceptibility category (S,
I or R) was assigned for each strain and antimicrobial
agent tested and from all isolates in the triplicate or du-
plicate sets, irrespective of breakpoint criteria used. The
overall percentage susceptibility category agreement for
each antimicrobial agent was established by calculating
the average of each strain percentage concordance. The
susceptibility category agreement for each year was the
average of each of the concordances for each agent. Due
to the confidential nature of the EQA, all results were
aggregated by year and antimicrobial.
Troubleshooting
Any laboratory that reported more than 5% of strains
with MICs > 2 MIC log2 dilutions from the modal MIC
was contacted to identify problems with contamination,
reagents, testing and interpretation.
Results
Antimicrobial susceptibility testing methods
The Etest (or more rarely other MIC gradient strip tests)
was the most common antimicrobial susceptibility test-
ing method, used in 55.0% of laboratories in 2007–2011
and 76.8% in 2012–2016 (Table 1). The use of disk diffu-
sion as the sole method decreased from 21.4% in 2007–
2011 to 3.2% of laboratories in 2012–2016, when most
laboratories had replaced their disk diffusion methods
with Etest due to its better performance in the EQAs in
general, and the recommendations by the Euro-GASP.
The most frequently used agar media or agar base for
the antimicrobial susceptibility testing was GC agar base
(63.4% of laboratories in 2007–2011 and 53.7% in 2012–
2016). An increased use of non-selective Thayer-Martin
and non-specified agar/s accounted for the reduction in
the use of GC agar over the two time periods. Guide-
lines/breakpoints from the Clinical and Laboratory Stan-
dards Institute (CLSI) [16] were adhered to most frequently
in the first five-year time period (69.8%), whereas break-
points from the European Committee on Antimicrobial
Susceptibility testing (EUCAST) [17] were the most com-
mon in the second five-year time period (increased from
6.5 to 65.3%) (Table 1). Most variation in the applied SIR
breakpoints was observed for azithromycin (Table 2)
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with some harmonisation to EUCAST breakpoints ob-
served from 2007 (0%) to 2012 (42.9%). However, many
different breakpoints were used also for cefixime, ceftriax-
one, ciprofloxacin and spectinomycin (Table 3).
All centres using the disk diffusion method referred to
the antibiotic contents recommended by the CLSI [16],
with exception of the azithromycin (15 μg) and gentami-
cin (10 μg) disks for which CLSI does not have any rec-
ommendations. The majority of the centres using disk
diffusion method also adhered to the recommended
CLSI zone diameter breakpoints [16], again with the ex-
ception of the azithromycin resistance zone diameter
breakpoints of ≤25mm, ≤27 mm (BSAC) and ≤ 30mm
and gentamicin which has no defined SIR breakpoints.
Antimicrobial susceptibility category agreement
The overall antimicrobial susceptibility category agree-
ment was consistently very high for spectinomycin (mean:
99.0%; range over the years: 96–100%), β-lactamase testing
(98.6%; 98–100%) and ceftriaxone (97.2%; 94–100%). The
concordance was also high for ciprofloxacin (95.9%; 89–100%)
and cefixime (92.3%; 88–95%). However, for azithromycin the
concordance was lower and fluctuated substantially
over the years (84.3%; 68–97%) (Fig. 1). The lowest
concordance for azithromycin (68%) was noted in
2016. Consensus antimicrobial susceptibility categories
were not assigned for gentamicin as no international
organisation has stated any SIR breakpoints for inter-
pretation of results.
The susceptibility category agreement was either the
same or higher for agar dilution compared with Etest,
with ceftriaxone (2012–2015) being the exception. In
general, the susceptibility category agreement over the
two time periods of 2007–2011 and 2012–2015 was low-
est for azithromycin (88 and 83%, respectively) and high-
est for spectinomycin (99%) (Table 4).
Concordance of MIC
Overall, high proportions of the reported MICs of each
antimicrobial agent were within one MIC log2 dilution
(+/− two-fold variation) of the modal MIC, that is, gen-
tamicin (95%), cefixime (93%), ciprofloxacin (92%), spec-
tinomycin (91%), azithromycin (89%), and ceftriaxone
(85%) (Table 5). Ninety percent of the total MICs were
Table 1 Details of antimicrobial susceptibility testing methods used in the European gonococcal External Quality Assessments
(EQAs)
2007–2011 (n=131a) 2012–2016 (n=95a; no EQA in 2013)
No. % No. %
Antimicrobial susceptibility test Etestb 72 55.0 73 76.8
Agar dilution 26 19.8 13 13.7
Disk diffusion 28 21.4 3 3.2
Disk diffusion and Etests 5 3.8 6 6.3
Culture media/base GC agar base 83 63.4 51 53.7
Chocolatised blood agar 33 25.2 23 24.2
Diagnostic sensitivity (DST) agar 7 5.3 5 5.3
Thayer-Martin agar (non-selective) 5 3.8 10 10.5
Blood agar base 2 1.5 1 1.1
None specified 1 0.8 5 5.3
Guidelines/breakpoints c CLSI 97 69.8 23 24.2
None specified 17 12.2 1 1.1
GRASP – United Kingdom 7 5.0 4 4.2
CACFM – France 3 2.2 4 4.2
SRGA – Sweden 5 3.6 0 0.0
EUCAST 9 6.5 62d 65.3
WHO 1 0.7 1 1.1
CLSI Clinical and Laboratory Standards Institute [16], GRASP Gonococcal Resistance to Antimicrobials Surveillance Programme [34], CA-SFM Committee of the
French Society for Microbiology (http://www.sfm-microbiologie.org), SRGA Swedish Reference Group for Antibiotics (no longer operational), EUCAST European
Committee on Antimicrobial Susceptibility testing [17], WHO World Health Organization
aSome methods and guidelines changed throughout the time periods for some laboratories. Thus, analysis of the comparison of methods was performed using
each laboratory for each year to give a total of 131 comparisons for 2007–2012 and 95 for 2012–2016
bDuring recent years, some countries have also used other MIC gradient strip tests
cn = 139 for guidelines/breakpoints as some laboratories used more than one guidance on methodology/breakpoints over the time period
dIncludes one laboratory that also used BSAC disk diffusion breakpoints for azithromycin
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also within one MIC log2 dilution of the modal MIC
during the two five-year periods (2007–2011 and 2012–
2016), with exception of azithromycin (88% in 2012–
2016) and ceftriaxone (84% in 2007–2011 and 88% in
2012–2016). In both time periods and for all antimicro-
bial agents combined, ≥97% of isolates were within two
MIC log2 dilutions (+/− four-fold variation) of the modal
MIC. The overall concordance did not change over the
two five-year time periods (Table 5).
The overall MIC concordances for each EQA distri-
bution were ≥ 85% (mean: 90.7%; range: 85–94%)
and ≥ 95% (97.6%; 95–99%) within one and two MIC
log2 dilutions of the modal MIC, respectively (Fig. 2).
Modal MICs for the eight WHO strains [15], used 29
times throughout the years, varied by one MIC log2
dilution, except for WHO M and ciprofloxacin which
varied from 1 to 4 mg/L between two distributions,
but the category remained the same, resistant. All
susceptibility categories were identical except for
WHO K and cefixime between two distributions (S
and R), however the modal MIC was the same at
0.25 mg/L.
Troubleshooting
More than 5% variation from the modal MIC was mainly
identified in laboratories that did not yet participate in
Euro-GASP decentralised testing. Issues identified and
mostly corrected included use of media suboptimal for
N. gonorrhoeae antimicrobial susceptibility testing, the
use of MIC gradient strip tests other than Etests (Bio-
Merieux), suboptimal reading of the MIC gradient strips,
mis-interpretation of the colour change with nitrocefin,
contamination and transcription errors.
Discussion
An increasing number of laboratories participated in the
ECDC Euro-GASP EQA; 27 in 2016 compared with 16
in 2009. Etest was the most common methodology and
GC agar base the most frequently used agar. In the last
5 years, there was a marked shift among participants to
the use of EUCAST [17] breakpoints from the CLSI [16]
breakpoints, most likely influenced by Euro-GASP and
the publication of the EU case definitions in August
2012 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2012:262:0001:0057:EN:PDF), which include
definitions of antimicrobial resistance and state that
EUCAST clinical breakpoints [17, 18] should be ad-
hered to. However, the lack of a recommended method-
ology for N. gonorrhoeae susceptibility testing by
EUCAST might result in some laboratories continuing
to use the CLSI breakpoints [16], which are inherently
linked to the CLSI methodology, which may impact the
interpretation. The harmonisation of antimicrobial sus-
ceptibility testing methods in the latter five-year period
(2012–2016) in Europe is a substantial improvement
compared with when the first EQA was performed and
generally no common methods were used [13]. How-
ever, even though methods and SIR breakpoints have
increasingly been harmonised, the overall impact on
the validity of results has been very limited since 2007,
as the percentage susceptibility category agreement and
MIC concordances changed very little between the two
five-year periods. Nevertheless, Euro-GASP will work
together with EUCAST to establish best practice so
laboratories across Europe can use standardised
antimicrobial susceptibility testing methods for N.
gonorrhoeae.
Table 2 Different MIC breakpoints for azithromycin used in the European gonococcal External Quality Assessments (EQAs) from
2007 to 2012
No. of laboratories*
(n = 104)
No. of laboratories
2007 (n = 12)
No. of laboratories
2012 (n = 14)
Azithromycin MIC breakpoints (mg/L)
S ≤ I R >
31 (29.8%) 4 (33.3%) 4 (28.6%) 0.5 – 0.5
29 (27.9%) 0 6 (42.9%) 0.25a 0.5a 0.5a
11 (10.6%) 2 (16.7%) 1 (7.1%) 1 – 1b
7 (6.7%) 2 (16.7%) 0 0.5 1 1
6 (5.8%) 1 (8.3%) 0 2 – –
6 (5.8%) 0 2 (14.3%) 0.25 – 0.25
1 (1.0%) 0 0 0.125 0.25–0.5 0.5
1 (1.0%) 0 0 0.125 0.25–1 1
1 (1.0%) 1 (8.3%) 0 0.25 0.5–1 1
1 (1.0%) 1 (8.3%) 0 4
10 (9.6%) 1 (8.3%) 1 (7.1%) None given
Note: Detailed interpretative MIC data was only available until 2012. Adherence to published breakpoints collected post-2012
*Includes total number of participants at each distribution, i.e. the same laboratory will be counted at each distribution
aCurrent EUCAST breakpoints
bUS GISP alert value MIC (https://www.cdc.gov/std/gisp/GISP-Protocol-May-2016.pdf)
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The United States Food and Drug Administration
(FDA) recommends that essential agreement (within one
MIC log2 dilution of the modal MIC) and antimicrobial
susceptibility category agreement should be at a mini-
mum 90% for each antimicrobial agent [19]. In the
present study, the overall concordance of antimicrobial
susceptibility categories in each year reached this target
(≥91%), which is a major improvement compared with
the first EQA performed in 2003 (> 70%). This demon-
strates an improved level of comparability of antimicro-
bial susceptibility results, despite the diversity of
methods. In future Euro-GASP EQAs, categorical agree-
ment using a known number of non-susceptible strains
and the number of very major, major and minor errors
will be established, as recommended by CLSI [20]. The
comparability of Etest and agar dilution observed in this
study, has also been observed elsewhere, particularly for
cephalosporins [21–23]. MIC differences in our study
could be due to agar media and inoculum size differ-
ences as established previously [24, 25], along with
varying levels of comparability between different disk
diffusion methods and agar dilution and/or Etests [26–
30]. Identified agar media differences in this study (data
not shown) in general agree with data presented from
other studies, including that cephalosporin MICs were
generally slightly higher from agar dilution with GC agar
compared with Etests [21–23], MICs from Etests with
chocolate agar were higher [31], as well as differing MIC
variation depending upon which media was used for
agar dilution [32, 33]. It was suggested by Liao et al. [31]
that laboratories should adhere to CLSI media recom-
mendations (GC agar base with 1% growth supplement)
[16], however the lack of commercial, off-the-shelf op-
tions of this medium makes this challenging for labora-
tories who do not have in-house agar-plate pouring
facilities.
Discrepancies in susceptibility categories were gener-
ally because the MICs for EQA panel isolates were on or
very close to the breakpoints, particularly for azithromy-
cin in 2016 (68%), as well as for ciprofloxacin in 2014
(89%) when a triplicate was composed of isolates with
MICs exactly on the resistance breakpoint. The use of
triplicates/duplicates allows laboratories to investigate
their own intra-laboratory concordance. However, if
strains with MICs exactly on or very close to a break-
point are selected, the overall category agreement for
that antimicrobial agent can be highly affected. For this
reason comparisons over time are difficult, so the inclu-
sion of the same strains over the years, as achieved in
this EQA and with comparable results, is an important
aspect to consider when analysing EQA performance.
Even though strains with MICs close to a breakpoint can
impact on susceptibility category agreement, they are
clinically relevant, effectively challenge the antimicrobial
susceptibility testing in participating laboratories, and
should be included in EQAs. However, when interpret-
ing susceptibility category results it is important to con-
sider the actual MIC for individual strains in respect to
patient management and the MIC distribution for iso-
lates contributing to susceptibility surveillance data, so
isolates near or on breakpoints can be identified and ap-
propriate caution issued. Differences in breakpoints will
also impact on susceptibility category agreement, for ex-
ample ten different breakpoint schemes for azithromycin
were used by EQA participants from 2007 to 2012, and
the breakpoints for cefixime were less harmonised dur-
ing earlier years, which may have contributed to the
lower concordance in 2012 (88%).
High comparability of results was also demonstrated
by the high proportion of isolates tested over the 10
years that were within one (≥90%) MIC log2 dilution and
two MIC log2 dilutions (≥97%) of the modal MIC. The
overall lower MIC concordance for ceftriaxone (85%)
may be due to the smaller dilution scales due to the
Table 3 Different MIC and zone diameter breakpoints for
cefixime, ceftriaxone, spectinomycin and ciprofloxacin used in
the European gonococcal External Quality Assessments (EQAs)
from 2007 to 2012
Antimicrobial
agent
MIC (mg/L) and zone diameter (mm) breakpoints
S ≤ I R >
Cefixime 0.06 ≥0.12 –
0.12 ≥0.25 –
0.12a – 0.12a
0.25b – –
≥31c – –
Ceftriaxone 0.06 ≥0.12 –
0.12 ≥0.25 –
0.12a – 0.12a
0.25b – –
≥35c – –
Spectinomycin 64a – 64a
32 – 32
32b 64b 64b
≥18c 15 – 17c ≤14c
Ciprofloxacin 0.03 0.06 - 0.5 0.5
0.03 – 0.03
0.03a – 0.06a
0.12 – 0.25
0.06b 0.12 - 0.5a 0.5b
≥41c 28 – 40c ≤27c
Note: Detailed interpretative MIC data was only available until 2012.
Adherence to published breakpoints collected post-2012
aCurrent EUCAST breakpoints [17]
bCurrent CLSI breakpoints [16]
cZone diameter breakpoints (mm)
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mostly lower ceftriaxone MICs and requiring more pre-
cision, e.g. at 0.004, 0.008 and 0.016 mg/L, as compared
with other antimicrobial agents with higher MICs in the
dilution scales such as 4, 8, 16 mg/L. The lower MIC
concordance for azithromycin (89%) was likely affected
by the fact that MIC testing for azithromycin is very sen-
sitive to minor differences in methodologies, in particu-
lar the medium used and pH (which is affected by the
concentration of CO2), as has been demonstrated previ-
ously [33, 34]. Full concordance in antimicrobial suscep-
tibility categories and MICs will likely never be possible,
due to the inherent inter-assay variation of any testing
method, and particularly not before there is a complete
harmonisation of antimicrobial susceptibility testing
methods.
The use of the same WHO strains over the years
allowed the measurement of variability over time, which
was shown to be very low in this EQA. The present
study has shown that the inter-laboratory reproducibility
was high amongst participating laboratories, comparable
in different distributions and years, and the use of stan-
dardised quality control strains [15] allows improved
comparison of results over time and between as well as
within laboratories.
The Euro-GASP EQA revealed high levels of compe-
tence and capability in recovering and testing strains of
Table 4 Overall concordance (%) of susceptibility category agreement for all EQA distributions and methods 2007–2011 and 2012–
2015 (no EQA in 2013)
2007–2011 2012–2015 (no EQA in 2013)a
All methods (n = 131)b Etest (n = 72)c Agar dilution (n = 26) All methods (n = 66)b Etest (n = 52)c Agar dilution (n = 11)
Azithromycin 88 85 97 83 80 92
Cefiximed 95 93 99 91 91 91
Ceftriaxone 98 97 98 96 97 96
Ciprofloxacin 95 96 97 96 96 96
Spectinomycin 99 99 99 99 99 100
a2016 results not included as only two laboratories performed agar dilution in 2016 so concordance was not calculated
bIncludes disk diffusion results
cSome countries have also used other MIC gradient strip tests
dNot tested prior to 2010
Fig. 1 Overall antimicrobial susceptibility category agreement in the European gonococcal External Quality Assessments (EQAs), 2007–2016 (no
EQA in 2013). Note: Cefixime was not tested before 2010
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Fig. 2 MIC concordance within one and two MIC log2 dilutions of the modal MIC in the European gonococcal External Quality Assessments
(EQAs), 2007–2016 (no EQA in 2013). *contains isolates from 2010 (11–15) and 2011 (1–15)
Table 5 MIC concordance and variation from the modal MIC in the European gonococcal External Quality Assessments (EQAs),
2007–2016 (no EQA in 2013)
Azithromycin Cefiximea Ceftriaxone Ciprofloxacin Gentamicina Spectinomycin Total
No. % No. % No. % No. % No. % No. % No. %
2007–2011 Within 1 MIC log2 dilution
b 1284 90 301 94 1331 84 1502 94 233 99 1038 91 5690 90
Within 2 MIC log2 dilutions 123 99 13 98 172 95 80 99 2 100 76 98 466 98
> 2 MIC log2 dilutions 19 1 6 2 76 5 24 1 0 0 26 2 151 2
Total no. of isolates with MIC data 1426 320 1579 1606 235 1140 6307
2012–2016 Within 1 MIC log2 dilution
b 701 88 757 93 728 88 728 90 482 93 660 92 4056 91
Within 2 MIC log2 dilutions 65 96 33 97 77 97 45 96 30 99 45 98 295 97
> 2 MIC log2 dilutions 28 4 22 3 27 3 36 4 4 1 11 2 128 3
Total no. of isolates with MIC data 794 812 832 809 516 716 4479
All years Within 1 MIC log2 dilution
b 1985 89 1058 93 2059 85 2230 92 715 95 1698 91 9745 90
Within 2 MIC log2 dilutions 188 98 46 98 249 96 125 98 32 99 121 98 761 97
> 2 MIC log2 dilutions 47 2 28 2 103 4 60 2 4 1 37 2 279 3
Total no. of isolates with MIC data 2220 1132 2411 2415 751 1856 10,785
aCefixime and gentamicin were not included in the 2007–2009 External Quality Assessment distributions
bEssential agreement
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unknown phenotype. The high level of comparability
over the 10 years of the EQA indicates that high quality
data are produced by the Euro-GASP participants and
gives confidence in decentralised testing and comparison
of antimicrobial susceptibility surveillance data in the
EU/EEA. The results from this EQA compared well with
similar national schemes in Canada (> 90% for MIC and
interpretation concordance) [35], India (82% interpret-
ation concordance) [36] and Australia (3.1% error rate in
respect to penicillin MICs) [32], even though the
Euro-GASP EQA is regional with many different partici-
pating countries, which by default means more variabil-
ity in methodologies. A quality control comparison
programme for the Latin America and the Caribbean
GASP region recently reported that most participants
had acceptable results and the impact of the different
methods on the results was also highlighted [37].
It should be noted that the Euro-GASP laboratories
are frequently experienced national reference labora-
tories with a high level of expertise and access to
training and advice from the Euro-GASP coordinators.
In contrast, the global GASP coordinated by the
WHO includes antimicrobial susceptibility data from
both experienced as well as less experienced labora-
tories. It would be exceedingly valuable to implement
a global EQA scheme, particularly in regions not par-
ticipating in existing schemes, to monitor and support
comparability of antimicrobial susceptibility surveil-
lance data from different countries and laboratories
globally. In addition, the use of a global EQA could
support primary diagnostic laboratories that perform
antimicrobial susceptibility testing for patient manage-
ment and local surveillance studies to ensure ad-
equate quality. The crucial need for this was
illustrated in a national survey in the United Kingdom
[38], where low levels of QA in gonococcal antimicro-
bial susceptibility procedures were identified. Confi-
dence in the reporting of patient related antimicrobial
susceptibility results is essential to avoid administer-
ing inappropriate treatment. A global EQA would
additionally allow the global dissemination of import-
ant reference strains for QA and clinical strains with
interesting/emerging resistance profiles or diagnostic-
ally challenging characteristics, and provide a further
opportunity for laboratories to achieve accreditation
standards.
Conclusions
Gonorrhoea remains a public health concern because
of the increasing incidence and the threat of multidrug-
resistant N. gonorrhoeae. Strengthening surveillance of
gonococcal antimicrobial susceptibility is imperative
worldwide and, in Europe, Euro-GASP has been
expanding annually. The high level of QA of the data
from Euro-GASP and other similar surveillance pro-
grammes is essential in order to identify novel emer-
ging resistance, appropriately monitor antimicrobial
resistance trends and to ensure national and inter-
national gonorrhoea treatment guidelines are updated
based on high quality and valid antimicrobial suscepti-
bility data.
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